Holen Sie sich die Stockscreener-App
20.90
21.62%
-5.83
Schlusskurs vom Vortag:
$26.73
Offen:
$18.94
24-Stunden-Volumen:
3.64M
Relative Volume:
4.64
Marktkapitalisierung:
$1.24B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-131.11M
KGV:
-9.6114
EPS:
-2.1745
Netto-Cashflow:
$-102.47M
1W Leistung:
-16.63%
1M Leistung:
-20.97%
6M Leistung:
-37.93%
1J Leistung:
+77.24%
1-Tages-Spanne:
$18.66
$21.44
1-Wochen-Bereich:
$18.66
$29.56
52-Wochen-Spanne:
$11.70
$40.65
Tyra Biosciences Inc Stock (TYRA) Company Profile
Firmenname
Tyra Biosciences Inc
Sektor
Branche
Telefon
(619) 728-4760
Adresse
2656 STATE STREET, CARLSBAD
Compare TYRA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
20.82 | 1.60B | 0 | -131.11M | -102.47M | -2.1745 |
VRTX
Vertex Pharmaceuticals Inc
|
520.43 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
802.59 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.56 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.13 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.47 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Guggenheim | Buy |
| 2026-04-06 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-02-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-02-10 | Eingeleitet | William Blair | Outperform |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-05-21 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-07 | Eingeleitet | UBS | Buy |
| 2024-10-18 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-08-15 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-30 | Eingeleitet | Wedbush | Outperform |
| 2023-02-03 | Eingeleitet | Oppenheimer | Outperform |
| 2022-06-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-03-08 | Hochstufung | Jefferies | Hold → Buy |
| 2021-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2021-10-11 | Eingeleitet | BofA Securities | Buy |
| 2021-10-11 | Eingeleitet | Cowen | Outperform |
| 2021-10-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Tyra Biosciences Inc Aktie (TYRA) Neueste Nachrichten
Tyra Biosciences (TYRA) Shares Plunge 22% as Bladder Cancer Drug Trial Falls Short - Blockonomi
Why This Biotech Stock Just Plummeted To A 10-Month Low - Investor's Business Daily
Tyra reports 79% response rate in Phase 2 cancer trial - grafa.com
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress - Barron's
Why is Tyra Biosciences stock plunging today? - Investing.com
Tyra Biosciences stock tumbles 30% on phase 2 trial results By Investing.com - Investing.com India
Tyra drops after mid-stage trial data for lead asset in bladder cancer - Seeking Alpha
Tyra Bioscience Reports Promising Phase 2 Dabogratinib Data - TipRanks
Tyra Biosciences reports positive Phase 2 SURF302 results, 60 mg QD chosen for registrational adjuvant plan - TradingView
Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib - PR Newswire
Tyra Biosciences to present at Cantor Global He... - Pluang
Tyra Biosciences sets virtual chat, investor meetings Sept. 9 - Stock Titan
A Quick Look at Today's Ratings for TYRA BIOSCIENCES, INC.(TYRA.US), With a Forecast Between $39 to $56 - Moomoo
Piper Sandler reiterates Tyra Biosciences stock rating ahead of data By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Tyra Biosciences stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Tyra Biosciences stock rating at buy - Investing.com
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $39 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Tyra Biosciences downgraded to Hold ahead of ke... - Pluang
Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readouts - Seeking Alpha
TYRA Stock Heads For Best Day In Nearly 10 Months — Sets Date For Key Phase 2 Bladder Cancer Drug Readout - Asianet Newsable
Tyra Bio rises on upcoming mid-stage trial data (TYRA:NASDAQ) - Seeking Alpha
Initial results for an oral bladder cancer drug will be discussed Sept. 9 - Stock Titan
How Tyra Biosciences Inc. (TYRA) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Tyra Biosciences draws industry focus with IR NMIBC research at IBCG26 retreat - Traders Union
Tyra Biosciences (TYRA): Can Dabogratinib Redefine FGFR3-Driven Bladder Cancer? - RTTNews
Tyra Biosciences Inc (TYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CCORF Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Tyra (TYRA) Results Check: EPS Falls Short of Its Estimate in the Current Update; Post-Earnings: The Market Price Moves 0.65% Higher in the Latest ReadingFinancial Data - vinanet.vn
Tyra’s one-drug, three-indication bet nears its first phase 2 test - Pharma Voice
Farallon Capital Management Slashes Tyra Biosciences (TYRA) Stak - GuruFocus
Tyra Biosciences Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Tyra Biosciences tests innovative therapy in SURF302 for intermediate-risk bladder cancer - Traders Union
Tyra Biosciences (NASDAQ: TYRA): What Comes Next for Its Pipeline? - Kalkine Media
Tyra Biosciences (NASDAQ:TYRA) Stock Price Up 6.2%Time to Buy? - MarketBeat
TYRA Q2 2026 Earnings: EPS Miss Slightly Overshadowed by 6.98% Share AdvanceBasic EPS Analysis - vinanet.vn
TYRA Q2 2026 Earnings: EPS Misses Estimates by 4.14% as Shares Gain 1.08%Healthcare Earnings Report - vinanet.vn
TYRA Q2 2026 Earnings: Wider-than-Expected Loss of -$0.69 per Share, Yet Stock Rises 1.08%Dividend Growth Analysis - vinanet.vn
Walleye Capital LLC Acquires Shares of 347,898 Tyra Biosciences, Inc. $TYRA - MarketBeat
TYRA Biosciences (TYRA) holder reports 3.55M-share, 6% beneficial stake - Stock Titan
Tyra Biosciences examines FGFR3 gene impact on cell growth disorders - Traders Union
Farallon group trims Tyra Biosciences (TYRA) holdings to 6,000 shares, 0% stake - Stock Titan
Avoiding Lag: Real-Time Signals in (TYRA) Movement - Stock Traders Daily
Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.82, Implies 94% Upside - TradingView
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Cuts Target Price to $39 - Moomoo
BofA Adjusts Price Target on Tyra Bioscience to $39 From $42 - marketscreener.com
TYRA's dabogratinib trial in 2026 could validat... - Pluang
Tyra Biosciences: SURF302 Is A Worthwhile Binary Bet (NASDAQ:TYRA) - Seeking Alpha
HC Wainwright Brokers Lower Earnings Estimates for TYRA - MarketBeat
Tyra Biosciences Inc (TYRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TYRA Q1 2026 Earnings: Wider-than-Expected Loss Reflects Continued Pipeline InvestmentFinancial Health Score - vinanet.vn
Finanzdaten der Tyra Biosciences Inc-Aktie (TYRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.83%
2.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):